Efficacy of Treatment of MS with IFN B-1b or Glatiramer Acetate by Monthly Brain MRI in the BECOME Study
Neurol 72:1976-1983,1972, Cadavid,D.,et al, 2009
Neutralizing Antibodies to Interferon Beta: Assessment of Their Clinical and Radiographic Impact: An Evidence Report
Neurol 68:977-984, Goodin,D.S.,et al, 2007
Mangnetic Resonance Imaging Effects of Interferon Beta-1b in the BENEFIT Study: Integrated 2-Year Results
Arch Neurol 64:1292-1298, Barkhof,F.,et al, 2007
Effect of Interferon B-1b in MS, Assessment of Annual Accumulation of PD/T2 Activity on MRI
Neurol 54:200-206, Zhao,G.J.,et al, 2000
A 29-Year-Old Man with Multiple Sclerosis
JAMA 280:1432-1439, Rudick,R.A., 1998
Character of MRI Response to Trtm with Interferon Beta-1B:Enhancing MRI Lesion Freq as Prim Outcome Measure
Neurol 49:862-869, Stone,L.A.,et al, 1997
Neutralizing Antibodies During Treatment of Multiple Sclerosis with Interferon Beta-1b
IFNB MS Study Group & UBC MS. MRI Analysis Group, Neurol 47:889-8946., , 1996
Interferon Beta-1b in the Trtm of MS:Outcome of the Randomized Controlled Trial
IFNB Study Gr, Neurol 45:1277-12851995., , 1995
Effect of Interferon-B on Blood-Brain Barrier Disrupt Demonst by Contrast MRI in Relapsing-Remitting MS
Ann Neurol 37:611-619, Stone,L.A.,et al, 1995
Are Magnetic Resonance Findings Pred of Clinical Outcome in Therapeutic Trials in MS? The Dilemma of Interferon-B
Ann Neurol 36:14-18, McDonald,W.I.,et al, 1994
Interferon Beta-1b is Effective in Relapsing-Remitting MS
Clinical Results of a Placebo-Controlled Trial, IFNB MS Study Grp, Neurol 43:655-661, 64193., , 1993
Interferon Beta-1b is Effective in Relapsing Remitting MS, MRI Analysis Results of Placebo-Control Trial
Neurol 43:662-667, 6411993., Paty,D.W.,et al, 1993
Superior MRI Outcomes with Alemtuzumab Compared with Subcutaneous Interferon �-1a in MS
Neurol 87:1464-1472, Arnold, D.L.,et al, 2016
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 373:1418-1428, Kappos, L.,et al, 2015
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
NEJM 362:402-415, 456, Cohen,J.A.,et al, 2010
Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis
NEJM 354:911-923,965, Rudick,R.A.,et al, 2006
Enhanced Benefit of Increasing Interferon Beta-1a Dose and Frequency in Relapsing Multiple Sclerosis
Arch Neurol 62:785-792, Schwid,S.R.,et al, 2005
Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis
NEJM 353:369-374,414,432, Kleinschemidt-DeMasters,B.K. &Tyler,K.L., 2005
Interferon Beta-1a for Brain Tissue Loss in Patients at Presentation with Syndromes Suggestive of Multiple Sclerosis: A Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 364:1489-1496,1463, Filippi,M.,et al, 2004
Validation of Diagnositc Magnetic Resonance Imaging Criteria for Multiple Sclerosis and Response to Interferon B1a
Ann Neurol 53:718-724, Barkhof,F.,et al, 2003
An Open-Label Trial of Combination Therapy With Interferon B-1a and Oral Methotrexate in MS
Neurol 58:314-317, Calabresi,P.A.,et al, 2002
Benefit of Interferon B-1a on MSFC Progression in Secondary Progressive MS
Neurol 59:679-687, Cohen,J.A.,et al, 2002
Effect of Early Interferon Treatment on Conversion to Definite Multiple Sclerosis: A Randomised Study
Lancet 357:1576-1582,1547, Comi,G.,et al, 2001
Randomized Controlled Trial of Interferon-beta-1a in Secondary Progressive MS
Neurol 56:1505-1513, Li,D.K.B.,et al, 2001
PRISMS-4: Long-Term Efficacy of Interferon-B-1a in Relapsing MS
Neurol 56:1628-1636,1620, The PRISMS Study Group, 2001
Magnetic Resonance Imaging Results of the PRISMS Trial:A Randomized, Double-Blind, Placebo-Controlled Study of Interferon-B1a in Relapsing-Remitting Multiple Scleroosis
Ann Neurol 46:197-206, Li,D.K.B.,et al, 1999
Evidence of Interferon B-1a Dose Response In Relapsing-Remitting MS, The OWIMS Study
Neurol 53:679-686, The Once Weekly Interferon for MS Study Group (OWI, 1999
Interferon-B-1a in Relapsing-Remitting Multiple Sclerosis:Effect on Hypointense Lesion Volume on T1 Weighted Images
JNNP 67:579-584, Gasperini,C.,et al, 1999
Effect of Steroids on Gd-Enhancing Lesions Before & During Beta Interferon 1a Trtm in Relapsing Remitting MS
Neurol 50:403-406, Gasperini,C.,et al, 1998
Randomised Double-Blind Placebo-Controlled Study of Interferon B-1a in Relapsing/Remitting Multiple Sclerosis
Lancet 352:1498-1504,1486, PRISMS, 1998
Central Nervous System Lymphoma: Characteristic Findings on Traditional and Advanced Imaging
AJNR 32:984-992, Haldorsen, I.S.,et al, 2011
In Vivo Mapping of Amyloid Toxicity in Alzheimer Disease
Neurol 72:1504-1511, Frisoni,B.G.,et al, 2009
CT and MRI Findings of Intracranial Lymphoma
AJR 184:1679-1685, Slone,H.W.,et al, 2005
Differentiation of Toxoplasmosis and Lymphoma in AIDS Patients by Using Apparent Diffusion Coefficients
AJNR 24:633-637,554, Camacho,D.L.A.,et al, 2003
Mass Lesions of the Brain in AIDS: The Dilemmas of Distinguishing Toxoplasmosis from Primary CNS Lymphoma
AJNR 24:554-555, Berger,J.R., 2003
Primary Lymphoma of the Central Nervous System: Typical and Atypical CT and MR Imaging Appearances
AJR 176:1319-1326, Erdag,N.,et al, 2001
Primary Lymphoma of the Pituitary: An Emerging Clinical Entity
J Clin Endocrinol Metab 86:4567-4575, Giustina,A.,et al, 2001
Evaluation and Management of Intracranial Mass Lesions in AIDS
Rpt of Quality Stnds Subcomm of the AAN, Neurol 50:21-261998., , 1998
Acute Leukoencephalopathies:Differential Diagnosis and Investigation
The Neurologist 4:148-166, Weinshenker,B.G.,et al, 1998
Diagnosis of AIDS-Related Focal Brain Lesions
Neurol 48:687-694, Antinori,A.,et al, 1997
The Variable MR Appearance of Primary Lymphoma of the Central Nervous System:Comparison with Histopathologic Features
AJNR 18:563-572, Johnson,B.A.,et al, 1997
Comparison of T2-Weighted & Fluid-Attenuated Inversion-Recovery Fast Spin-Echo MR Seq in Intracerebral AIDS-Assoc Dis
AJNR 18:1601-1609, 16111997., Thurnher,M.W.,et al, 1997
Fulminant Cerebral Lymphoma In AIDS
AJNR 17:157-160, Ghiang,F.L.,et al, 1996
Neuroimaging Findings in Patients with AIDS
Clin Inf Dis 22:906-919, Walot,I.,et al, 1996
Management Protocol for an Enhancing Cerebral Lesion in HIV Infection
Conn Medicine 60:649-651, Finelli,P.F., 1996
Central Nervous System Lymphoma not Detectable on Single-Photon Emission CT with Thallium 201
AJNR 17:1687-1690, Fisher,D.C.,et al, 1996
Evaluating Contrast-Enhancing Brain Lesions in Patients with AIDS by Using Positron Emission Tomography
Ann Int Med 123:594-598, Pierce,M.A.,et al, 1995
Contrast-Enhanced Fast MRI in Differentiating Brain Toxoplasmosis and Lymphoma in AIDS Patients
J Comput Assist Tomogr 18:714-718, Laissy,J.P.,et al, 1994
Diagnosis of Intracranial Lymphoma in Patients with AIDS:Value of 201TI Single-Photon Emission Computed Tomography
AJR 163:417-421, O'Malley,J.P.,et al, 1994